Published on
June 3, 2022
- 23:37 GMT
Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity BOTHELL, WA, UNITED STATES, June 3, 2022 /EINPresswire.com/ -- Sound Biologics (Qilu Puget …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
